Senthil Damodaran

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

(2023)10.1158/1078-0432.c.6530036

Top 100%

0DataRank

Top 100%0 citations

Xiaofeng Zheng, Christian X. Cruz Pico, Tae‐Beom Kim, Ken Chen, Anil Korkut +9 more

Papers

Driven by 21 papers — median percentile 0. Top paper: “Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer”.

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0144

N/A

2.0DataRank · unranked

79 citations

Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven R. Garber +26 more

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer

npj Breast Cancer(2025)10.1038/s41523-025-00722-1

N/A

0.550DataRank · unranked

18 citations

Nicole M. Kettner, Danielle Kwiatkowski, Senthil Damodaran, Yan Wang, David L. Ramírez +6 more

Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Investigational New Drugs(2023)10.1007/s10637-023-01357-4

N/A

0.285DataRank · unranked

5 citations

Ryan Sun, Roland L. Bassett, Lei Huo, Jeffrey T. Chang, Mediget Teshome +24 more

Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.1067

N/A

0DataRank · unranked

3 citations

Danielle Kwiatkowski, Senthil Damodaran, Nicole M. Kettner, David L. Ramírez, Dan S. Gombos +5 more

Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Frontiers in Artificial Intelligence(2022)10.3389/frai.2022.876100

N/A

0DataRank · unranked

21 citations

Ranran Wu, Jody V. Vykoukal, Eunice Murage, Rachelle Spencer, Jennifer B. Dennison +18 more

Resolving clonal substructure from single cell genomic data using CopyKit

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.09.483497

N/A

0DataRank · unranked

13 citations

Emi Sei, Junke Wang, Aislyn Schalck, Yun Yan, Alexander Davis +14 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Research Square(2022)10.21203/rs.3.rs-2248209/v1

N/A

0DataRank · unranked

0 citations

Turçin Saridogan, Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca +11 more

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers

Cancer Research(2023)10.1158/0008-5472.can-23-0705

N/A

0DataRank · unranked

53 citations

Nicole M. Kettner, Xiayu Rao, Cassandra Santaella Bishop, Tuyen Bui, Hannah F. Wingate +10 more

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

npj Breast Cancer(2023)10.1038/s41523-023-00573-8

N/A

0DataRank · unranked

29 citations

Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans +8 more

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer

Scientific Reports(2023)10.1038/s41598-023-46586-y

N/A

0DataRank · unranked

15 citations

Argun Akçakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott +11 more

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

Cancer(2023)10.1002/cncr.34773

N/A

0DataRank · unranked

5 citations

Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina A. Piha‐Paul, Julia Ann Moore +18 more

Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530597

N/A

0DataRank · unranked

0 citations

Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven R. Garber +26 more

Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530597.v1

N/A

0DataRank · unranked

0 citations

Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven R. Garber +26 more

Data from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

(2023)10.1158/1078-0432.c.6530036

Top 100%

0DataRank

Top 100%0 citations

Xiaofeng Zheng, Christian X. Cruz Pico, Tae‐Beom Kim, Ken Chen, Anil Korkut +9 more

Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1948

N/A

0DataRank · unranked

22 citations

Erkan Yuca, Kurt W. Evans, Ming Zhao, Takanori Maejima, Tsuyoshi Karibe +12 more

IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer

npj Precision Oncology(2025)10.1038/s41698-025-01041-1

N/A

0DataRank · unranked

14 citations

Tuyen Bui, Juliana Navarro-Yepes, Sanaz Ghotbaldini, Bethanie Quintela, Catherine K. Luo +19 more

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3952

N/A

0DataRank · unranked

7 citations

Filip Jankú, Siqing Fu, Ecaterina E. Dumbrava, David S. Hong, Daniel D. Karp +20 more

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

Investigational New Drugs(2020)10.1007/s10637-020-00995-2

N/A

0DataRank · unranked

28 citations

Gaiane M. Rauch, Tanbin Rahman, Meghan Karuturi, Elizabeth E. Ravenberg, Jason B. White +14 more

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

ESMO Open(2025)10.1016/j.esmoop.2025.104136

N/A

0DataRank · unranked

4 citations

Chieh Tseng, Hai T. Tran, Aung Naing, Ecaterina E. Dumbrava, DD Karp +9 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4048

N/A

0DataRank · unranked

28 citations

Xiaofeng Zheng, Christian X. Cruz Pico, Tae‐Beom Kim, Ken Chen, Anil Korkut +9 more

Senthil Damodaran

Indexed papers

Top data-sharing exemplar

Papers